Speaker Credentials
OMS-II
Speaker Credentials
MS
College
Dr. Kiran C. Patel College of Osteopathic Medicine, DO
Medical Specialty
Neurosurgery
Format
Presentation
Start Date
November 2024
End Date
November 2024
Track
4
Abstract
Title: Use of Electrical Bone Growth Stimulators in High-Risk Patients Following Spinal Fusion Authors: Soumya Malhotra, BA., MS1 & Khavir Sharieff, DO, MBA2 1Class of 2027, Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine, Fort Lauderdale, FL 2Assistant Professor of Surgery, Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine, Tampa Bay, FLNova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine Objective: This study aimed to elucidate the advantages of EBGSs following high-risk spinal fusions. Background: Pseudarthrosis is a condition where bones fail to fuse after an injury or surgery. It causes significant morbidity in patients with a history of smoking, diabetes, spinal surgery, failed fusions, rheumatoid arthritis, or spondylolisthesis. Electrical bone growth stimulators (EBGSs) have gained popularity in pseudarthrosis management. No reviews have been conducted evaluating pseudarthrosis prevention with EBGS use following high-risk spinal fusions. Methods: A systematic search was performed in September 2024 across PubMed, EMBASE, Web of Science, Ovid MEDLINE using PRISMA guidelines. Keywords included “bone growth stimulators”,” spinal fusions,” ” pseudarthrosis,” among others. Only studies in English reporting EBGS use following high-risk spinal fusion were included. Descriptive statistics were used to analyze the data. Results: 269 articles reported using EBGSs in spinal fusions, ten studies met the criteria (7 RTCs, 1 non-RTC, and 2 case-controlled). Eight used direct current EBGSs, and two reported pulsed EBGSs. 736 EBGS-treated patients were identified with an 18.18 month (SD +/- 12.14) mean follow-up. The average fusion rate was 81.8% (SD+/- 19.99). Objective pain assessment (0-60 pain index) showed 12% or higher pain relief with measurable functional improvements such as distance walking, return to daily work, and social living. Conclusion: This study highlights EBGSs as a viable option in preventing pseudarthrosis following high-risk spinal fusion surgery. However, the variability in study design warrants further research to assess the advantages of EBGSs post-spinal fusion. Grants: This study was not funded by any sponsor/funder.
Included in
Bioelectrical and Neuroengineering Commons, Biomedical Commons, Biomedical Devices and Instrumentation Commons, Biotechnology Commons, Cellular and Molecular Physiology Commons, Equipment and Supplies Commons, Medical Biotechnology Commons, Medical Neurobiology Commons, Molecular and Cellular Neuroscience Commons, Molecular, Cellular, and Tissue Engineering Commons, Musculoskeletal Diseases Commons, Musculoskeletal, Neural, and Ocular Physiology Commons, Musculoskeletal System Commons, Neurosciences Commons, Neurosurgery Commons, Other Analytical, Diagnostic and Therapeutic Techniques and Equipment Commons, Other Neuroscience and Neurobiology Commons, Surgery Commons, Surgical Procedures, Operative Commons, Systems and Integrative Physiology Commons, Therapeutics Commons, Wounds and Injuries Commons
Use of Electrical Bone Growth Stimulators in High-Risk Patients Following Spinal Fusion
Title: Use of Electrical Bone Growth Stimulators in High-Risk Patients Following Spinal Fusion Authors: Soumya Malhotra, BA., MS1 & Khavir Sharieff, DO, MBA2 1Class of 2027, Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine, Fort Lauderdale, FL 2Assistant Professor of Surgery, Nova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine, Tampa Bay, FLNova Southeastern University Dr. Kiran C. Patel College of Osteopathic Medicine Objective: This study aimed to elucidate the advantages of EBGSs following high-risk spinal fusions. Background: Pseudarthrosis is a condition where bones fail to fuse after an injury or surgery. It causes significant morbidity in patients with a history of smoking, diabetes, spinal surgery, failed fusions, rheumatoid arthritis, or spondylolisthesis. Electrical bone growth stimulators (EBGSs) have gained popularity in pseudarthrosis management. No reviews have been conducted evaluating pseudarthrosis prevention with EBGS use following high-risk spinal fusions. Methods: A systematic search was performed in September 2024 across PubMed, EMBASE, Web of Science, Ovid MEDLINE using PRISMA guidelines. Keywords included “bone growth stimulators”,” spinal fusions,” ” pseudarthrosis,” among others. Only studies in English reporting EBGS use following high-risk spinal fusion were included. Descriptive statistics were used to analyze the data. Results: 269 articles reported using EBGSs in spinal fusions, ten studies met the criteria (7 RTCs, 1 non-RTC, and 2 case-controlled). Eight used direct current EBGSs, and two reported pulsed EBGSs. 736 EBGS-treated patients were identified with an 18.18 month (SD +/- 12.14) mean follow-up. The average fusion rate was 81.8% (SD+/- 19.99). Objective pain assessment (0-60 pain index) showed 12% or higher pain relief with measurable functional improvements such as distance walking, return to daily work, and social living. Conclusion: This study highlights EBGSs as a viable option in preventing pseudarthrosis following high-risk spinal fusion surgery. However, the variability in study design warrants further research to assess the advantages of EBGSs post-spinal fusion. Grants: This study was not funded by any sponsor/funder.